Bendamustine
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Explore 128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified →Floatz Rating
B61/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07072221CT.gov Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients | — | Recruiting | — | — | — |
NCT04083495CT.gov CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma | — | Recruiting | — | — | — |
NCT02535247CT.gov Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT02168140CT.gov CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01716806CT.gov A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | — | Completed | — | — | — |
NCT01644253CT.gov Phase 1b Safety and Efficacy Study of TRU-016 | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral T-Cell Lymphoma, Not Otherwise Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bendamustine (this asset) | The First Affiliated Hospital of Soochow University | P2 | B · 61 |
| Adriamycin | BeBetter Med Inc | P4 | BBB |
| Pralatrexate | Peking University People's Hospital | P4 | BBB |
| Prednisone | Tarapeutics Science Inc. | P4 | BBB |
| (+)-Vincristine | BeBetter Med Inc | P4 | BBB |
| Cyclophosphamide | Tarapeutics Science Inc. | P4 | BBB |
| Romidepsin | University of Virginia | P3 | BBB |
| Rivoceranib | Ruijin Hospital | P4 | BBB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
+42 more in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort
Other indications for Bendamustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 70 |
| Follicular Lymphoma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bendamustine in Peripheral T-Cell Lymphoma, Not Otherwise Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bendamustine-peripheral-t-cell-lymphoma-not-otherwise-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →